HIV

Tuberculosis (TB) remains an important public health problem, particularly among people infected with the human immunodeficiency virus (HIV). Read More

This month an international HIV prevention trial was launched that is testing the infection-preventing prowess of a monoclonal antibody called VRCO1. Read More

It’s been known for some time that the immune system can produce antibodies capable of “neutralizing” HIV, and stopping the AIDS-causing virus dead in its tracks. Read More

An international research team led by scientists from Vanderbilt University Medical Center has identified a genetic variant that protects people with HIV from developing active tuberculosis. The variant is near the gene encoding the infection-fighting cytokine IL-12. Read More

A $1.5 million Vanderbilt study is partnering with Nashville's First Response Center to curb HIV and hepatitis diagnoses in young black males at risk for HIV. Read More

The first study to suggest that major depressive disorder (MDD) is an independent risk factor for heart failure in HIV-positive adults has been published in Circulation. Read More

The Vanderbilt Institute for Global Health (VIGH) has received two new grants from the Fogarty International Center of the National Institutes of Health (NIH) to build HIV-focused research capacity with key partners in Zambia, Mozambique and Brazil. Read More

Vanderbilt University has received a five-year grant from the National Institutes of Health (NIH) to establish the Tennessee Center for AIDS Research with Meharry Medical College and the Tennessee Department of Health. Read More

Inhibitors of the enzyme phospholipase D1 suppress the replication of HIV-1, Vanderbilt investigators have discovered. Read More

With the help of a computer program called “Rosetta,” researchers at Vanderbilt University have “redesigned” an antibody that has increased potency and can neutralize more strains of the AIDS-causing human immunodeficiency virus (HIV) than can any known natural antibody. Read More

New findings underscore the attractiveness of the HIV capsid – the structure that encloses the viral genome – as a therapeutic target. Read More

If you’re a native of rural Mozambique who contracts HIV and becomes symptomatic, before seeking clinical testing and treatment, you’ll likely consult a traditional healer. Read More

Vanderbilt University’s Richard Caprioli, Ph.D., is participating in a national, federally funded collaboration to develop an intravaginal ring capable of delivering antiretroviral drugs to women at risk for HIV infection. Read More

Understanding how HIV infection affects immune system B cells may guide strategies for vaccine development. Read More

Vanderbilt researchers propose guidelines for defining patient retention in clinical studies – an important parameter that affects study conclusions and program evaluations. Read More

The protein APOBEC3G contributes to spontaneous control of HIV-1 in vivo and may provide therapeutic benefits. Read More

Anti-retroviral therapy can prevent tuberculosis, even in people with early HIV disease. Read More

Understanding how antibodies with long “loops” form may be important for HIV vaccine development. Read More

Research reveals clues to HIV risk in Chinese men who have sex with other men. Read More

An inexpensive, low-tech test for cervical cancer may be a good option for screening for the disease among HIV-infected women in developing countries. Read More